FDA panel recommends shifting diabetes CV safety studies to premarket

An FDA advisory committee Thursday recommended the agency modify diabetes drug safety guidelines to soften or eliminate requirements for postmarket cardiovascular outcomes trials of n https://www.biocentury.com/bc-extra/politics-policy/2018-10-25/fda-panel-recommends-shifting-diabetes-cv-safety-studies-